別品名 |
CCI-779; NSC 683864; rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate), Temsirolimus
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
1030.3
|
CAS RN® |
162635-04-3
|
化合物の概要 |
Analog of rapamycin.
|
参考文献 |
Geoerger B, Kerr K, Tang CB, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001 Feb 15;61(4):1527-1532. PMID: 11245461. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004 Jan 23;279(4):2737-2746. PMID: 14576155. Okui T, Shimo T, Fukazawa T, et al. Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction. Mol Cancer Ther. 2010 Nov;9(11):2960-2969. PMID: 20858724. Siracusa R, Paterniti I, Cordaro M, et al. Neuroprotective effects of temsirolimus in animal models of Parkinson's disease. Mol Neurobiol. 2018 Mar;55(3):2403-2419. PMID: 28357809.
|
|
メーカー |
品番 |
包装 |
LKT
|
T176503
|
100 MG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
保存温度 |
4℃
|
|